NASDAQ · JNJ
Healthcare · Drug Manufacturers - General
$276.32
Up+$10.15 (+3.81%)
Updated Nov 5, 2026, 5:23 AM
SID Score
7.5/10
Composite research score
Smart Money
50/100
Neutral
Price performance · JNJ
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
JNJ closed at $276.32 after 21 trading sessions, up 6.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $272.41 | $277.35 | $267.67 | $276.32 | 9.82M |
| Nov 3, 2026 | $268.51 | $271.07 | $265.28 | $266.17 | 6.51M |
| Nov 2, 2026 | $272.06 | $273.0141 | $267.435 | $270.56 | 8.26M |
| Oct 30, 2026 | $280.00 | $282.015 | $273.13 | $273.20 | 8.97M |
| Oct 29, 2026 | $275.31 | $278.05 | $273.595 | $275.20 | 6.02M |
| Oct 28, 2026 | $265.83 | $272.75 | $264.20 | $271.04 | 6.4M |
| Oct 27, 2026 | $265.25 | $269.09 | $264.83 | $268.73 | 5.77M |
| Oct 26, 2026 | $266.74 | $272.36 | $264.97 | $266.30 | 5.78M |
| Oct 23, 2026 | $265.82 | $266.025 | $262.40 | $263.81 | 5.31M |
| Oct 22, 2026 | $260.54 | $269.67 | $259.04 | $267.61 | 10.13M |
| Oct 21, 2026 | $257.50 | $257.80 | $254.56 | $257.78 | 6.56M |
| Oct 20, 2026 | $257.48 | $260.77 | $256.422 | $259.36 | 7.66M |
| Oct 19, 2026 | $254.43 | $255.56 | $251.50 | $253.79 | 8.85M |
| Oct 16, 2026 | $255.52 | $257.55 | $254.00 | $255.56 | 6.55M |
| Oct 15, 2026 | $257.11 | $262.445 | $252.62 | $253.28 | 9.28M |
| Oct 14, 2026 | $249.095 | $253.94 | $248.50 | $253.91 | 9.66M |
| Oct 13, 2026 | $254.56 | $256.1822 | $245.17 | $248.61 | 16.65M |
| Oct 12, 2026 | $261.60 | $264.39 | $260.3685 | $263.73 | 5.91M |
| Oct 9, 2026 | $255.09 | $261.61 | $254.985 | $261.44 | 5.73M |
| Oct 8, 2026 | $256.22 | $257.80 | $251.945 | $256.48 | 6.18M |
| Oct 7, 2026 | $256.21 | $260.68 | $255.73 | $258.45 | 5.41M |
The latest Smart Investors Daily articles mentioning JNJ.
Company
Market Activity
Research & News
JNJ research
Company profile and research snapshot.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 16, 2026 | Wells Fargo | Overweight | — |
| Oct 15, 2026 | Morgan Stanley | Overweight | — |
| Oct 14, 2026 | Leerink Partners | Outperform | — |
| Oct 14, 2026 | Wells Fargo | Overweight | — |
| Oct 14, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Nov 4, 2026
Key TakeawaysZimmer Biomet shares jumped 15% after third-quarter sales grew 3. 7% in constant currency and it raised its 2026 guidance.
Yahoo · Nov 4, 2026
Key TakeawaysModerna shares jumped 8% after its myeloma therapy, mRNA-2808, showed four confirmed responses among 11 heavily pretreated patients. The data shows Moderna’s mRNA can get the body to make three cancer drugs at once, though it’s years from challenging Johnson & Johnson, Pfizer and Regeneron.
Yahoo · Nov 4, 2026
A $500,000 portfolio of six blue-chip dividend growers kicks off thousands in annual income, but where you hold those shares determines how much of that income you actually get to keep.
Yahoo · Nov 4, 2026
Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson shares closed at $266.17, reflecting a modest intraday decline of 0.38%, per SID market data. Over the trailing twelve months, JNJ has delivered a 30.4% gain, significantly outperforming its historically defensive profile. Shorter-term momentum remains constructive, with one-month and three-month returns of 5.68% and 6.13%, respectively, according to Massive/Polygon data. The stock currently trades above both its 50-day moving average of $265.61 and its 200-day moving average of $248.64, confirming a sustained uptrend across multiple timeframes. However, the 14-day relative strength index stands at 73.5, placing JNJ in technically overbought territory and suggesting potential near-term consolidation. The company's beta of 0.349 underscores its low-volatility characteristics relative to the broader market. Average daily trading volume registers at approximately 8.82 million shares, supporting healthy liquidity for this $505.8 billion market capitalization healthcare conglomerate.
Johnson & Johnson currently trades at a price-to-earnings ratio of 20.30, positioning it at a moderate premium within the healthcare sector, per SID market data. The PEG ratio stands at 1.91, suggesting the stock is priced above its earnings growth rate on a one-to-one basis, according to SEC filings. The company's price-to-book ratio of 6.43 reflects the market's recognition of JNJ's extensive intangible asset base, including its pharmaceutical pipeline and consumer brand portfolio. On the income return front, Johnson & Johnson offers a dividend yield of approximately 2.45%, maintaining its long-standing appeal to income-oriented investors. At a market capitalization of $505.8 billion, JNJ ranks among the largest healthcare companies globally. The valuation metrics collectively indicate that the stock is trading at a premium that accounts for its diversified revenue streams, consistent cash generation, and defensive positioning within the broader equity market landscape.
Johnson & Johnson's composite smart money score registers at 50 out of 100, reflecting a neutral overall signal, per SID market data. Institutional ownership conviction is the standout metric, scoring a perfect 25 out of 25 according to 13F institutional filings, indicating that major fund managers maintain maximum-confidence positions in the stock. In contrast, insider activity scores a more modest 8.7 out of 25, with SEC Form 4 filings revealing 16 insider transactions over the past 90 days, comprising 7 purchases and 9 sales. The slight tilt toward insider selling suggests executives have been modestly reducing exposure, though the volume of purchases indicates continued internal confidence. Dark pool activity scores 9.4 out of 25, pointing to limited off-exchange institutional accumulation at current price levels. Congressional trading interest scores 7.0 out of 25, reflecting below-average legislative attention. The divergence between strong institutional conviction and moderate insider activity creates a mixed directional picture for smart money watchers tracking JNJ.
Johnson & Johnson has demonstrated a consistent pattern of meeting or exceeding analyst expectations across its most recent quarterly results. Per company earnings reports, JNJ posted earnings per share of $2.90 in its latest quarter against a consensus estimate of $2.85, delivering a $0.05 positive surprise. The prior quarter showed EPS of $2.70 versus the $2.67 estimate, a $0.03 beat. The earliest reported quarter reflected a narrow miss, with actual EPS of $2.46 falling one cent short of the $2.47 consensus. Most recently, the company reported $2.59 per share against an estimate of $2.53, representing a $0.06 upside surprise according to analyst estimates. Across the four reported periods, JNJ beat expectations in three out of four quarters, with cumulative surprise totaling a positive $0.13 per share. This earnings consistency reinforces the company's reputation for operational predictability within the healthcare sector.
Wall Street consensus on Johnson & Johnson remains firmly constructive, with recent analyst activity uniformly reflecting bullish positioning, per SID consensus data. In mid-October 2026, Wells Fargo reiterated its Overweight rating on two separate occasions, signaling sustained conviction in JNJ's forward trajectory according to Wall Street analyst reports. Morgan Stanley similarly maintained its Overweight classification, while both Leerink Partners and RBC Capital reaffirmed Outperform ratings on the same date. Notably, all five of the most recent analyst actions represent reiterations rather than upgrades or downgrades, indicating stable institutional sentiment with no erosion in confidence. The absence of any Hold or Underweight ratings among recent coverage updates reflects broad agreement that JNJ's risk-reward profile remains favorable at current levels. The clustering of reaffirmations immediately following the company's latest earnings report suggests that quarterly results reinforced existing investment theses. Zero downgrades across the most recent coverage cycle underscores Wall Street's durable positive stance on the healthcare conglomerate.
The latest Smart Investors Daily articles mentioning JNJ.
